Purpose: Cryoablation is gaining acceptance as a primary treatment of localized metastatic urologic malignancies as well as a salvage therapy. Anecdotal clinical reports suggest that cryoablation can induce a systemic antitumor immune response, which has been confirmed in animal models also. Materials and Methods: A review of the relevant literature was performed to suggest urologic applications of cryo-immunology. Results: This article reviews the existing evidence regarding cryo-immunology and discusses the mechanisms for generation of an anti-tumor immune response. Conclusions: Our findings suggest combining cryoablation with other immunotherapeutic approaches to devise a cryo-immunotherapeutic strategy with potential to impact the progression of metastatic disease. 
INTRODUCTION
Cryoablation, or tissue destruction by deep freezing and thawing, is a widely used treatment modality for the management of both benign conditions and localized cancer. Although cold temperature had been used therapeutically for centuries, 1 
Arnott
2 was the first to use it to treat cancer in the middle of the 19 th century when he used iced saline solutions to control advanced breast and uterine cancers. Towards the end of the 19 th century and beginning of the 20 th century, liquid air and liquid oxygen began to be used for the treatment of various skin diseases. 3, 4 Cryotherapy applications grew slowly until 1961, when Cooper and Lee 5 devised a cryosurgical unit capable of delivering liquid nitrogen (−196 o C). 6 They used it for the treatment of Parkinsonism. 7, 8 The pioneering work on cryosurgery in urology was done by Gonder et al, [9] [10] [11] who modified Cooper's unit for prostate ablation, first in dogs and then in humans. Their technique involved transurethral freezing with a single closed-probe system using liquid nitrogen. Cryosurgery was used initially for benign prostatic hypertrophy in patients unsuitable for surgery, but local complications were frequent.
With the advent of better treatment modalities for benign prostatic hypertrophy, the use of cryosurgery in the management of urologic conditions was abandoned. In the meantime, cryosurgery continued to develop in other specialties with improvements made in liquid nitrogen probes and heating devices. [12] [13] [14] 
CRYOBIOLOGY
Cryoablation induces tumor cell death directly by damage to cell membranes and organelles and indirectly by causing vascular compromise through thrombosis of small vessels. [27] [28] [29] [30] With falling temperatures, the cells dehydrate and proteins are with cryoablation, and coined the term "cryo-immunotherapy." 35, 36 They found enhancement of this immune response after repeated in situ freezing, which they explained was due to 
CRYO-IMMUNOLOGY

MECHANISMS OF THE CRYO-IMMUNE
RESPONSE
CONCLUSIONS
With increasing evidence of the ability of the adaptive immune system to fight cancer and the limitations of current treatment options for metastatic cancer, cryo-immunotherapy may provide a promising alternative in managing metastatic renal and prostate cancer and will possibly decrease the morbidity and mortality associated with advanced and metastatic disease.
